All In MedTech

FDA Clearance Tracker · P920023-S010

UROLUME(R) ENDOPROSTHESIS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 14, 2000 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 14, 2000

Approved

Time to decision

138 days

Received Sep 29, 1999. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P920023-S010
Device name
UROLUME(R) ENDOPROSTHESIS
Applicant location
Marlboro, MA
Received
Sep 29, 1999
Decided
Feb 14, 2000
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P920023

Device type

Device class
Class III

Every decision under product code MES

FDA's approval statement

As written in FDA's record.

Extend the shelf life expiration dating up to 5 years.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.